Tbx21 methylation as a potential regulator of immune suppression in cms1 subtype colorectal cancer

HIGHLIGHTS

• who: Yuanyuan Shen et al. from the Institute for Data Science and Informatics, University of Missouri, Columbia, MO, USA have published the article: TBX21 Methylation as a Potential Regulator of Immune Suppression in CMS1 Subtype Colorectal Cancer, in the Journal: Cancers 2022, 14, 4594. of 28/03/2020
• what: Enriched in High Expression and Low Methylation Patients To look at the question of molecular differences impacting survival in CMS1 patient subgroups, the authors completed DEG analysis, focusing on the differences between high-low and low-high patients . The authors further build on the data exhibited . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.